Amgen, Inc. (NASDAQ:AMGN)

Test tubes

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the May 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Test tubes

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Prescription drugs

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation Inc. (NASDAQ: MDVN) found itself in after ...
Read Full Story »
biotech word cloud

Analysts Make Major Changes to Top Biotech Ratings

At different times of the year, certain sectors come alive or slow down. Typically each year, the first quarter is the slowest for the biotechs, so many analysts tend to ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the March 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Pills and tablets

Regeneron and Sanofi Plan to Appeal Amgen Patent Verdict

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen Inc. (NASDAQ: AMGN) on a cholesterol drug patent. However, Regeneron ...
Read Full Story »
biotech word cloud

Short Sellers Back Off of Major Biotechs

The short interest data are out for the February 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Why Citi Sees Huge Upside in 4 Top Biotechs Now

If there was one sector inside of a broader health care theme that performed well through much of 2015, it was biotech. That was then, and this is now. A ...
Read Full Story »
graph

Short Interest Rises Across the Board in Major Biotechs

The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Major Biotech Short Interest Continues to Be Mixed

The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
ThinkstockPhotos-481735362

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

When some investors think about biotech, the first thoughts are of incredibly volatile companies, with clinical data and binary outcomes that can make the stocks swing up and down wildly. ...
Read Full Story »
Test tubes

Amgen Posts Handy Beat on Estimates and Guidance

Amgen Inc. (NASDAQ: AMGN) reported fourth-quarter financial results after the markets closed Thursday. The company had $2.61 in earnings per share (EPS) on $5.54 billion in revenue, compared to consensus ...
Read Full Story »
biotech word cloud

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech word cloud

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. There is a challenging macro setup, but headwinds combined with a relatively attractive valuation could carry ...
Read Full Story »